Background We conducted a cross-sectional analysis in a population-based cohort to compare the strength of the associations among various lipid parameters and the presence of atherosclerotic plaque in the proximal thoracic aorta. Methods As part of Aortic Plaques and Risk of Ischemic Stroke (APRIS) study, 464 subjects were studied (mean age 69 . 179 . 0, 251 males and 213 females), including 255 patients with first ischaemic stroke and 209 stroke-free controls. Presence and thickness of atherosclerotic plaque were assessed by transoesophageal echocardiography. Measured lipid parameters included total cholesterol, triglycerides, low-density lipoprotein, high-density lipoprotein, and non-high-density lipoprotein cholesterol, lipoprotein (a), apolipoprotein (Apo) B and A-I levels with their ratio. Results Overall, atherosclerotic plaque was detected in 326 subjects (70 . 4%) and 37 . 6% of these subjects (n 5 174) had atherosclerotic plaque Z4 mm. After adjusting for other significant predictors of atherosclerosis, high-density lipoprotein cholesterol level and Apo B/A-I ratio emerged as the strongest predictors of any atherosclerotic plaque (Po0 . 001 and P 5 0 . 004, respectively), followed by individual Apo B (P 5 0 . 015) and A-I (P 5 0 . 016) levels, triglycerides (P 5 0 . 027) and non-high-density lipoprotein cholesterol level (P 5 0 . 021). Total and low-density lipoprotein cholesterol levels were not significant predictors for any atherosclerotic plaque (P 5 0 . 273 and P 5 0 . 081, respec-tively). High-density lipoprotein cholesterol level (P 5 0 . 008) and Apo A-I (P 5 0 . 006) were also significant predictors of atherosclerotic plaque Z4 mm. Similar trends were observed after exclusion of subjects on cholesterol lowering drugs. Conclusion High-density lipoprotein cholesterol level and Apo B/A-I ratio, but not total or low-density lipoprotein cholesterol levels, were strongly associated with degree of proximal aortic atherosclerosis. 257 Ã P valueo0Á05. w Adjusted by age, gender, hypertension, diabetes, and current smoking.AP, atherosclerotic plaque; OR, odds ratio; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Apo B/A-I, apolipoprotein B to A-I ratio.
Background
Current lipid lowering guidelines recommend that therapy for preventing and managing cerebrovascular and cardiovascular disease (CVD) be targeted primarily at low-density lipoprotein (LDL) cholesterol (1) . Clinical studies such as Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) showed that lowering LDL reduces the plaque burden in the coronary arteries (2) (3) (4) . However, LDL may not be an optimal predictor of future cardiovascular events. High-density lipoprotein (HDL) cholesterol, which is known to be strongly, independently, and inversely associated with CVD, may be a new potential target (5) . Emerging data suggest that HDL cholesterol may be more predictive of actual atherosclerotic burden than LDL cholesterol (6, 7) . A recent post hoc analysis from Treating to New Targets (TNT) study showed that the HDL cholesterol level in patients receiving statins was predictive of major cardiovascular events, even among study subjects with LDL cholesterol levels below 70 mg/dl (8) .
In addition, determining the level of HDL apolipoprotein component (apolipoprotein A-I) and its ratio to apolipoprotein B in atherogenic lipoproteins (Apo B/A-I ratio) could theoretically improve the prediction of atherosclerotic burden. Large-scale studies, such as Apolipoprotein-related MOrtality RISk (AMORIS) and INTERHEART (9, 10) , have unambiguously shown that the Apo B/A-I ratio is a robust predictor for future CVD events.
The measurement of thoracic aortic atherosclerotic plaque (AP) thickness by transoesophageal echocardiogram (TEE) is a well-validated technique for evaluating the progression of atherosclerosis (11, 12) , and AP is an increasingly recognised stroke risk factor, particularly among the elderly (13, 14) . A plaque thickness cutoff of 4 mm is widely acknowledged as clinically relevant for risk stratification. The French Aortic Plaque in Stroke (FAPS) study indicated that not only that plaque thickness was associated with stroke risk, but also that the risk was significantly greater in those with a plaque thickness Z4 mm (14) . The odds ratio (OR) for stroke in patients with plaques o1 mm was 1Á0; for 1-3Á9 mm plaques, it was 3Á9; and for plaques Z4 mm, the OR was 13Á8. This cutoff for risk stratification has subsequently been used in numerous studies (15) (16) (17) .
As part of the NINDS-funded Aortic Plaques and Risk of Ischemic Stroke (APRIS) study, we conducted a cross-sectional analysis in a population-based sample to compare the strength of the associations among various lipid parameters and the presence and thickness of AP in the proximal thoracic aorta.
Methods
The APRIS study, in which TEE was performed in patients with acute ischaemic stroke and in matching control subjects, affords a rare opportunity to examine risk factors associated with aortic arch atherosclerosis. All participants come from the Northern Manhattan area of New York City.
The participants in the APRIS study were recruited from a larger population-based cohort study among residents of northern Manhattan [Northern Manhattan Study (NOMAS)]. The methods of subject recruitment and enrolment in NOMAS have been described in previous publications (18) . Because aortic AP is rarely observed at a younger age, participants in APRIS were limited to those Z55 years of age. The present report is based on 255 patients with first ischaemic stroke consecutively referred for TEE, and 209 stroke-free controls drawn from the NOMAS cohort and matched to cases by age, gender and race-ethnicity. The Institutional Review Board at Columbia-Presbyterian Medical Center approved the NOMAS study; all participants gave consent directly or through a surrogate when appropriate.
Baseline evaluation was performed at enrolment as reported previously (18) . Standard techniques were used to measure blood pressure, height, weight, and fasting glucose. Fasting lipid panels (including total cholesterol, LDL, HDL, and triglycerides) along with lipoprotein (a), Apo B and Apo A-I were measured with a Hitachi 705 automated spectrometer (Boehringer, Indianapolis, IN, USA).
Cardiovascular risk factors were collected by direct interview using standardised questions adapted from the Centers for Disease Control and Prevention Behavioral Risk Factor Surveillance System or by medical record review (19) . Hypertensive status was defined as a systolic blood pressure recording Z140 mmHg or a diastolic blood pressure recording Z90 mmHg based on the mean of the two readings of the blood pressure measurements, a patient's self-report of a history of hypertension, or antihypertensive medication use. A history of diabetes mellitus was defined by a patient's selfreport of such a history, insulin use, oral hypoglycaemic use, or a fasting glucose Z126 mg/dl. Hypercholesterolaemia was defined as total serum cholesterol 4240 mg/dl, a patient's self-report of hypercholesterolaemia or the presence of lipidlowering treatment. Cigarette smoking was defined by a current history of cigar or cigarette smoking (smoking within a year). Body mass index was calculated as weight (kg) divided by height (m) squared. The presence of atrial fibrillation was documented based on the results of a current or past ECG. Coronary artery disease included history of myocardial infarction or typical angina or the patient's reporting of a positive diagnostic test (stress test, coronary angiography) or drug treatment. Carotid duplex Doppler examination to assess for stenosis was performed in 216 stroke patients (84Á7%) and in 168 control subjects (80%).
The method for assessment of AP has been described fully in previous publications (20) . Briefly, transoesophageal echocardiography was performed with an Agilent (Santa Clara, CA, USA) 2500, 4500, or 5500 system with a 5 MHz omniplane transducer. Aortic plaques in proximal thoracic aorta (i.e., proximal to the take-off of the left subclavian artery) was assessed by a single experienced echocardiographer (M. D. T.) blinded to the subject's risk factors. Aortic plaque thickness was measured in the horizontal plane, perpendicular to the major axis of the aortic lumen as reported previously (20) . Aortic plaque was deemed present when its thickness was equal to, or more than 2 mm. Large AP was defined thickness equal to or greater than 4 mm. This cutoff has been shown to correlate with risk of stroke in prior studies (14) and is generally accepted as clinically relevant (14) (15) (16) (17) (18) . The presence of plaque ulcerations and/or superimposed mobile components was also recorded. Echocardiographers performing the TEE were blinded to subject's lipid parameters and other risk factors.
Statistical analysis
The distributions of lipid parameters and other variables were examined. Differences between mean values were assessed by Student's t-test, between proportions by w 2 -test. Univariate and multivariate logistic regression analyses were performed to test the association between lipid parameters and any AP or large AP, before and after adjustment for potentially confounding cardiovascular risk factors (age, gender, hypertension, diabetes, and cigarette smoking). The lipid parameters that were significantly associated with the presence of any AP were categorised into quartiles, and association between the presence of AP and the highest quartile (vs. lowest) of the lipid parameter distributions was analysed. The same analyses were performed for stroke patients and control subjects separately. Statistical significance was determined at the a 5 0Á05 level with two-sided tests. Statistical analyses were performed with sas 9.1 computer software (SAS Institute Inc., Cary, NC, USA).
Results

Baseline characteristics
We enrolled 464 subjects (251 males, 213 females), including 255 patients with first ischaemic stroke and 209 stroke-free controls matched to cases by age, gender and race-ethnicity. Participants were predominantly males (54Á1%), elderly (mean age 69Á179Á0), and hypertensive (76Á3%) ( Table 1 ). The prevalence of hypercholesterolaemia, diabetes, and smoking were 44Á2%, 33Á3%, and 17Á4%, respectively. Atrial fibrillation was present in 8Á6% of our cohort. Carotid stenosis Z60% was more frequent in stroke patients than in control subjects, as were many of the cardiovascular risk factors (Table 1 ). Only one control subject (0Á6%) had evidence of carotid stenosis Z60% by Doppler ultrasound. The aetiology of stroke was thought to be lacunar in 61 patients (23Á9%), atherosclerotic in 51 patients (20Á0%), cardioembolic in 44 (17Á2%). A stroke of unknown cause (cryptogenic) was diagnosed in 92 of 255 stroke patients (36Á1%).
Overall, AP of any thickness was detected in 326 subjects (70Á4%); 174 subjects (37Á6%) had large AP (Z4 mm), 67 subjects (14Á5%) had ulcerated or mobile AP and five subjects (1Á1%) had both characteristics. Subjects with AP were older (71Á079Á0 vs. 64Á677Á2, Po0Á001), more likely to smoke (19Á9% vs. 11Á4%, P 5 0Á029), and to have hypercholesterolaemia (47Á7% vs. 36Á6%, P 5 0Á028) and coronary artery disease (15Á5% vs. 5Á8%, P 5 0Á004). The number of subjects with significant carotid stenosis (Z60%) increased as the degree of AP progressed. The prevalence was 3Á6%, 7Á5% and 10Á9% for subjects with no AP, any AP and large AP, respectively (P 5 0Á15 for AP vs. no AP, and P 5 0Á006 for large AP vs. no AP).
Predictors of any AP and large AP (Z4 mm)
After adjustment for major cardiovascular risk factors (Table  2) , HDL and Apo B/A-I ratio emerged as the strongest predictors of any AP, followed by individual Apo B and A-I levels, TG and non-HDL level. Only HDL and Apo A-I ratio were significant predictors of large AP (Z4 mm). The association patterns for these lipid parameters and AP or large AP (Z4 mm) showed similar trends when stroke patients and control subjects were analysed separately ( Table 3) ; HDL and non-HDL cholesterol were significant predictors of any plaque in stroke patients. HDL and Apo A-I levels trended for prediction of large plaque in controls but did not reach statistical significance. Small sample size (53 out of 209) prevented the calculation for Apo B/A-I ratio in controls.
The two parameters that had the strongest association with AP in the overall study group (HDL and Apo B/A-I ratio) were categorised into quartiles and the association between each quartile and the presence of any AP was evaluated. The adjusted OR for any AP for the highest quartile of HDL (vs. lowest quartile) was 0Á33 (95% CI 0Á17-0Á67, P 5 0Á002). Compared with the lowest quartile, the second and third quartiles were not significant predictors for any AP. For Apo B/ A-I ratio, the adjusted OR for any AP in the highest quartile (vs. lowest quartile) was 4Á05 (95% CI 1Á05-10Á9, P 5 0Á006), and the adjusted OR for any AP in second and third quartile (vs. lowest quartile) was 2Á71 (95% CI 1Á21-6Á07, P 5 0Á016).
Analysis excluding subjects on cholesterol-lowering agents
Drug information was available in 388 subjects, 84 (21Á6%) were on cholesterol-lowering agents. We conducted a separate analysis on the 304 subjects not on cholesterol-lowering treatment. Two hundred and forty-nine subjects (69Á1%) had AP of any thickness and 130 subjects (34Á3%) had large AP. The HDL cholesterol level remained a significant predictor for any AP and large AP (Table 4 ). Triglycerides, Apo B and Apo B/A-I ratio predicted the presence of any AP but not large AP.
Discussion
This is the first study to assess lipid risk factors for AP in an elderly cohort that included both stroke patients and normal volunteers. Our results support a previously described association between atherosclerosis and the cholesterol balance determined as HDL or alternatively as Apo B/A-I ratio, and extends that observation to the aortic arch, a region of particular interest for its potential for embolism to the brain. These associations were present independently of other traditional atherosclerotic risk factors, including age, gender, hypertension, diabetes, and smoking, and also demonstrated in a subgroup that excluded patients on cholesterol-lowering therapy, a potential confounder of the association between lipid parameters and aortic atherosclerosis. There were both a continuous relationship of HDL and Apo B/A-I ratio with AP thickness and an association with AP thickness of Z4 mm, a thickness cutoff that strongly correlates with risk of stroke (14) . Moreover, there was a dose-response relationship between quartiles of Apo B/A-I ratio and HDL cholesterol and AP presence, further reinforcing the strength of the finding. Previous small echocardiographic studies addressing the association between lipid parameters and aortic atherosclerosis yielded discordant results. An association between LDL (but not HDL) and aortic atherosclerosis has been occasionally observed (21) but not confirmed in other studies (22, 23) . This discordance is probably due to different patient selection, as patients referred to TEE for various clinical reasons were included. In contrast, the APRIS study enabled us to assess stroke patients and a sample of the general population, and demonstrated strong and significant association between AP and HDL but not LDL. This study confirmed the inadequacy of total cholesterol levels as indicators of the atherosclerotic burden.
Both clinical observations and basic laboratory experiments support the hypothesis that HDL is antiatherogenic (24) and has direct and indirect anti-inflammatory effect that may translate into antithrombotic activities (25) . A recent longitudinal study demonstrated that a high level of HDL cholesterol reduces plaque growth in subjects with preexisting carotid atherosclerosis (26) , which is in accordance with our observation. However, over half of our patients had an ischaemic stroke, and this might have been at least a partial confounder in the relationship between HDL and aortic atherosclerosis, because tissue inflammation and caloric deficit in these patients can reduce HDL after stroke (27) . We found, however, that there was a significant association between any aortic atherosclerosis and HDL levels even when the stroke patients and controls were analysed separately.
Given the strong negative association of AP and HDL, our results indicate that low levels of HDL deserve special attention in clinical practice in patients who have significant risk factors for stroke, and that HDL levels may be better targets for treatment strategies than LDL cholesterol in patients with AP (28) . Pharmacological elevation of HDL cholesterol is considered to be a promising strategy for achieving further reductions in cardiovascular risk in statin-treated patients (29) although initial experiences in the ILLUMINATE study did not show benefits with a cholesterylester transfer protein inhibitor (30) . Another potential HDL-raising drug is nicotinic acid, and this agent has been shown to reduce coronary events in the Coronary Drug Project and slow progression of atherosclerosis (31) . However, it has not been tested in reducing strokes or aortic disease.
The evidence for the Apo B/A-I ratio as a strong new risk factor for CVD is increasing (9, 10) . Apolipoproteins tend to remain stable with age and severity of disease, whereas lipoproteins such as LDL and HDL tend to decrease over time. A large-scale cross-sectional study in asymptomatic young individuals demonstrated the strong correlation of apolipoproteins with carotid intima-media thickness, and their superior prognostic value for predicting cardiovascular events (32, 33) . However, studies comparing the utility of apolipoprotein with lipoprotein measurements in detecting subclinical atherosclerosis have been limited. Furthermore, data on risk factors for AP are less readily available. No previous large studies have reported a positive association between apolipoprotein fractions and aortic atheromas. In the 
present study, Apo B/A-I ratio emerged as the strongest predictors of aortic atherosclerosis, and both individual Apo B and A-I levels were also significantly associated with presence of aortic plaques. Increased levels of triglyceride-rich lipoproteins are known to be associated with low levels of HDL. In patients with carotid stenosis, increased triglyceride-rich lipoproteins (but not LDL) and reduced HDL correlated strongly with presence of echolucent, rupture-prone plaques (34, 35) . Elevated triglycerides level is also a component of the metabolic syndrome, and trends toward higher triglyceride levels have been reported in patients who subsequently experience ischaemic stroke (36) (37) (38) . However, triglyceride levels vary considerably, making it difficult to evaluate them as a risk factor for stroke. In our study, triglyceride levels showed significant association with any AP, but not with large AP.
A recent study has shown that statin therapy reduces AP progression, accompanied by a reduction in total cholesterol and LDL, but not with changes in HDL (39) . Another study showed no difference in total cholesterol, LDL, HDL, or triglycerides between stroke patients with or without progression of AP (40) . We conducted a separate analysis on patients who were free of cholesterol lowering medications, and HDL cholesterol level remained a significant predictor for both any AP and large AP. The effect of conventional cholesterol treatment on AP remains to be further investigated.
Limitations
Because of their small number, we could not consider complex atheromatous plaques (i.e., ulcerated or mobile plaques) as a dependent variable in the analysis. In addition, different stroke subtypes (i.e., cryptogenic vs. known cause) could not be individually analysed. Furthermore, our sub-analyses on stroke and control subjects are limited due to small number of subjects, as reflected in wide confidence intervals. Therefore, we avoided drawing any significant conclusions relying on the results of these sub-analyses.
Our control subjects were questioned on neurological symptoms and signs to assure stroke-free status on enrolment in the study, but head MRI was not performed at enrolment. Therefore, asymptomatic brain infarcts could not be considered in the analysis. Finally, due to the cross-sectional design of our study, the association between Apo B/A-I ratio or HDL and AP does not imply a causal relationship. The actual relationship between Apo B/A-I ratio or HDL and atherosclerosis remains to be determined from large-scale prospective studies.
Conclusions
In summary, our study supports the role of HDL cholesterol, and alternatively Apo B/A-I ratio, as predictors of proximal aortic arch atherosclerosis. Further studies are necessary to explore the hypothesis that targeted therapies may decrease the risk of events in this patient population.
